Previous meta-analyses have primarily pooled the cardiovascular effects of GLP-1 RAs in patients with T2DM (12–15), meanwhile only a few have evaluated the cardiovascular benefits of semaglutide specifically in individuals with overweight or obesity (16, 17). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.